Generic Product News

Pharmacy Times, July 2014 Digestive Health, Volume 80, Issue 7

Marketed by: Teva Pharmaceutical Industries Ltd

Compare to: Lunesta Tablets (Sunovion Pharmaceuticals)

Indication: Teva Pharmaceutical Industries Ltd has announced the launch of eszopiclone tablets, CIV, the generic equivalent to Sunovion Pharmaceuticals’ Lunesta Tablets. Eszopiclone tablets are indicated for the treatment of insomnia, and have been shown to decrease sleep latency and improve sleep maintenance. Eszopiclone tablets are available in 1-, 2-, and 3-mg strengths.

Dosage Form: Tablets: 1, 2, and 3 mg

For More Information: www.tevagenerics.com

Calcipotriene and Betamethasone Dipropionate Ointment

Marketed by: Sandoz

Compare to: Taclonex Ointment (LEO Pharma A/S)

Indication: Sandoz has announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, a generic equivalent to Leo Pharma A/S’s Taclonex Ointment. Calcipotriene and betamethasone dipropionate ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of psoriasis vulgaris in patients 18 years and older. Sandoz is marketing calcipotriene and betamethasone dipropionate ointment in 60- and 100-g tubes.

Dosage Form: Topical ointment: calcipotriene 0.005% and betamethasone dipropionate 0.064%

For More Information: www.us.sandoz.com

Clonidine Transdermal System, USP

Marketed by: Actavis

Compare to: Catapres-TTS (Boehringer Ingelheim)

Indication: Actavis has announced the launch of its generic version of Boehringer Ingelheim’s Catapres- TTS, following final approval of its Abbreviated New Drug Application by the FDA. Clonidine transdermal system, USP, is indicated for the treatment of hypertension, and provides continuous systemic delivery of clonidine for 7 days. Patches should be applied once every 7 days to a hairless area of the upper outer arm or chest. Each new application should be on a site different from the previous one.

Dosage Form: Transdermal patch: 0.1, 0.2, and 0.3 mg/day

For More Information: www.actavis.com

Olanzapine Orally Disintegrating Tablets

Marketed by: Mylan, Inc

Compare to: Zyprexa Zydis (Eli Lilly and Company)

Indication: Mylan, Inc, has announced the launch of olanzapine orally disintegrating tablets, a generic version of Eli Lilly and Company’s Zyprexa Zydis Tablets, after FDA approval of the Abbreviated New Drug Application for the product. Olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for maintenance treatment of bipolar I disorder.

Dosage Form: Orally disintegrating tablets: 5, 10, 15, and 20 mg

For More Information: www.mylan.com